Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 4/20 | 0.33 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.33 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.33 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.33 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 2/20 | 0.32 |
| ▸ | GALR3 | O60755 | 1/20 | 0.32 |
| ▸ | BLM | P54132 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | THRB | P10828 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | SLC22A16 | Q86VW1 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3623282 | 0.81 | TSHR (0.34) | TSHRCHRM2CHRM4CHRM1TBXA2R | |
| SCHEMBL3504549 | 0.79 | TSHR (0.33) | TSHRCHRM2CHRM4CHRM1TBXA2R | |
| SCHEMBL6293184 | 0.79 | POLB (0.33) | TSHRCHRM2CHRM4CHRM1TBXA2R | |
| SCHEMBL7775047 | 0.76 | BTN3A1 (0.30) | TSHRCHRM2CHRM4CHRM1TBXA2R | |
| SCHEMBL80349 | 0.75 | TSHR (0.33) | TSHRTHRBALDH1A1 | |
| SCHEMBL16227463 | 0.74 | — | — | |
| Methacrylic Acid SCHEMBL5607189 | 0.71 | — | — | |
| SCHEMBL2812644 | 0.68 | ALDH1A1 (0.42) | TSHRTHRBALDH1A1 | |
| SCHEMBL29068293 | 0.68 | THRB (0.36) | TSHRTHRBALDH1A1 | |
| Phosphoric Acid SCHEMBL8763237 | 0.68 | TSHR (0.50) | TSHRCHRM2CHRM4CHRM1TBXA2R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 191 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3837306-B1 | FLUID FOR CONTROLLING THE PERMEABILITY OF A SUBTERRANEAN FORMATION, AND USE THEREOF | ENI SPA (IT) | 2026-05-06 | — | — | EP | claimed |
| EP-3988139-B1 | IN VIVO BULKING AGENT, INJECTION COMPRISING SAME, AND PREPARATION METHOD THEREFOR | UNIV KOREA RES & BUS FOUND (KR) | 2026-03-04 | — | — | EP | claimed |
| US-20260021030-A1 | FRAGRANCE-CONTAINING MICROPARTICLES | GIVAUDAN SA (CH) | 2026-01-22 | — | — | US | claimed |
| EP-3132810-B1 | PROSTHESIS FOR IN VIVO INSERTION, COATED WITH CROSS-LINKED POLYPHOSPHORYLCHOLINE | SEOUL NAT UNIV R&DB FOUNDATION (KR) | 2025-10-29 | — | — | EP | claimed |
| US-11925547-B2 | Prosthesis for in vivo insertion, coated with cross-linked polyphosphorylcholine | SEOUL NATIONAL UNIVERSITY R&DB FOUNDATION (KR) | 2024-03-12 | — | — | US | claimed |
| EP-3569623-B1 | VINYL-LACTAM-BASED HYDROGEL COATINGS | CONSEJO SUPERIOR INVESTIGACION (ES) | 2023-08-09 | — | — | EP | claimed |
| WO-2023000713-A1 | STRONG-ADHESIVE POLYELECTROLYTE HYDROGEL COATING AND PREPARATION METHOD THEREFOR | 浙江大学 | 2023-01-26 | — | — | WO | claimed |
| EP-3558510-B1 | ARRAY INCLUDING SEQUENCING PRIMER AND NON-SEQUENCING ENTITY | ILLUMINA INC (US) | 2022-11-23 | — | — | EP | claimed |
| EP-3778673-B1 | PHOSPHORYLCHOLINE GROUP AND SILICONE GROUP-CONTAINING COPOLYMER, POWDER COATED WITH SAID COPOLYMER AND PRODUCTION METHOD THEREFOR, AND USE OF SAID COPOLYMER AND SAID POWDER IN COSMETICS | KOSE CORP (JP) | 2022-11-02 | — | — | EP | claimed |
| US-20210378814-A1 | PROSTHESIS FOR IN VIVO INSERTION, COATED WITH CROSS-LINKED POLYPHOSPHORYLCHOLINE | SEOUL NAT UNIV R&DB FOUNDATION (KR) | 2021-12-09 | — | — | US | claimed |
| EP-3515993-B1 | METHOD FOR PRODUCING A WATER-SOLUBLE THERMALLY-CROSSLINKABLE POLYMERIC MATERIAL | ALCON INC (CH) | 2021-11-10 | — | — | EP | claimed |
| US-11129706-B2 | Prosthesis for in vivo insertion, coated with cross-linked polyphosphorylcholine | SEOUL NATIONAL UNIVERSITY R&DB FOUNDATION (KR) | 2021-09-28 | — | — | US | claimed |
| EP-3382002-B1 | COMPOSITION FOR CONTACT LENS | PEGAVISION CORP (TW) | 2021-08-04 | — | — | EP | claimed |
| EP-2988790-B1 | BIOACTIVE COATINGS | BIOINTERACTIONS LTD (GB) | 2021-04-28 | — | — | EP | claimed |
| EP-2723752-B1 | BIOCOMPATIBLE, BIOMIMETIC AMPHOLYTE MATERIALS | BIOINTERACTIONS LTD (GB) | 2020-08-05 | — | — | EP | claimed |
| EP-2644188-B1 | OIL-IN-WATER-TYPE EMULSION SKIN COSMETIC | SHISEIDO CO LTD (JP) | 2018-09-26 | — | — | EP | claimed |
| US-20180127529-A1 | Water-Absorbing (Meth) Acrylic Resin With Optical Effects, And Related Compositions | ELC MAN LLC (US) | 2018-05-10 | — | — | US | claimed |
| EP-3132810-A1 | PROSTHESIS FOR IN VIVO INSERTION, COATED WITH CROSS-LINKED POLYPHOSPHORYLCHOLINE | Seoul National University R&DB Foundation (KR) | 2017-02-22 | — | — | EP | claimed |
| US-20170035555-A1 | PROSTHESIS FOR IN VIVO INSERTION, COATED WITH CROSS- LINKED POLYPHOSPHORYLCHOLINE | SEOUL NATIONAL UNIVERSITY R&DB FOUNDATION (KR) | 2017-02-09 | — | — | US | claimed |
| EP-1846010-B1 | EXTERNAL SKIN AGENT COMPRISING MODIFIED CLAY FOR PREVENTING INFLAMMATION | POLA CHEM IND INC (JP) | 2011-08-03 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180127529-A1 | Water-Absorbing (Meth) Acrylic Resin With Optical Effects, And Related Compositions | MMAB, ASIC1, MAT1A | TSHR 3820/4885CHRM2 3470/4885CHRM4 2631/4885 |
| US-20260021030-A1 | FRAGRANCE-CONTAINING MICROPARTICLES | SGMS2, SGMS1, PHOSPHO1 | TSHR 2898/4885CHRM2 859/4885CHRM4 1390/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.